We have read with great interest the letter of the European Task Force on Atopic Dermatitis (ETFAD) on SARS‐CoV‐2‐infection and atopic dermatitis published in JEADV (March 2020)(1) in which the authors state: “Targeted treatment selectively interfering with type‐2 inflammation such as dupilumab is not considered to increase the risk for viral infections and might thus be preferred …in a situation such as COVID‐19 pandemic”.(1)